• linkedin
  • Increase Font
  • Sharebar

    Keep your patient moving: An overview of treatment options for constipation

    CONTINUING EDUCATION

    May 2016  

    Session code for pharmacists: 16DT28-JVX38 

    Session code for pharmacy technicians: 16DT28-TAK49

    This month’s CE activity, “Keep your patient moving: An overview of treatment options for constipation,” is open for pharmacists and pharmacy technicians.

    Pharmacists and pharmacy technicians can earn up to 2 hours of CPE credit for completing this knowledge-based activity from the University of Connecticut School of Pharmacy and Drug Topics.

    The goal of this program is to assist pharmacists and pharmacy technicians in their understanding of the role of linaclotide, lubiprostone, methylnaltrexone, and naloxegol in the treatment of constipation after conventional nonpharmacologic interventions and conventional laxatives such as bulking agents, osmotic laxatives, and stimulant laxatives have failed.

    To read and print the article with TEST QUESTIONS, click here.

    To proceed to the online exams and earn up to 2 CPE credits, click here to log in with the session code for pharmacists: 16DT28-JVX38 or the session code for pharmacy technicians: 16DT28-TAK49.

    Copy the appropriate session code above before logging into the Online CE Center. When the page for the Online CE Center opens, paste the session code into the appropriate field, under your NABP ID.

    First-time users must pre-register in the Online CE Center.

    _______________________________________________________________

    The login to the Online CE Center is https://web2.uconn.edu/pharmacyce/login.php.

    To review you registration page to ensure the data is up to date, or to register,
    go to https://web2.uconn.edu/pharmacyce/program_register.php.

    For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/.

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available